| Understanding pharmacological complement inhibition in paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape |
|
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria |
|
Hematology. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies |
|
Expert Opinion on Biological Therapy |
Myelodysplastic Syndromes (MDS) |
| Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study |
|
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| T-cell dysfunctions in myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Quality of life after immune suppressive therapy in aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
